ESLA$2.26
Chart
Performance
Key Stats
AI ESLA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldEstrella Immunopharma (ESLA) shows potential in its specific niche but faces significant financial challenges and weak market performance. Investors should exercise caution and consider its high-risk profile.
Thematic
Estrella Immunopharma operates in the promising biopharmaceutical sector, focusing on T-cell therapies for blood cancers and solid tumors. The underlying thematic trends of advancements in immunotherapy and cancer treatment are strong, but the company's specific stage of development and execution present challenges.
Fundamental
Estrella Immunopharma exhibits significant financial weaknesses, including no revenue, negative earnings, and substantial operating losses. While it holds some cash, its balance sheet shows a high proportion of current assets relative to liabilities, but its overall financial health is precarious due to its development stage.
Technical
Estrella Immunopharma's stock price has experienced a significant decline over the past year. While there are short-term trading signals that might suggest minor upticks, the overall trend and momentum indicators point towards continued weakness.
| Factor | Score |
|---|---|
| Immunotherapy & Cancer Treatment Advancements | 80 |
| Clinical Trial Progress & Regulatory Approvals | 50 |
| Biotech Investment Landscape | 60 |
| Strategic Partnerships | 70 |
| Market Penetration for Novel Therapies | 65 |
| Factor | Score |
|---|---|
| Valuation | 20 |
| Profitability | 5 |
| Growth | 0 |
| Balance Sheet Health | 70 |
| Cash Flow | 10 |
| Factor | Score |
|---|---|
| Trend Analysis | 15 |
| Momentum | 40 |
| Volume Confirmation | 40 |
| Support & Resistance | 30 |
| Moving Averages | 35 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Earnings Surprise
Estrella Immunopharma, Inc. reported an Earnings Per Share (EPS) of -0.06 for Q2 2025, which was 45.45% higher than the estimated -0.11.
Short-term Performance Strength
The stock has shown positive performance over the last 5 days (+4.12%) and 1 month (+3.29%), indicating recent investor interest.
Bearish Points (8)
Negative Earnings Per Share (TTM)
The trailing twelve months (TTM) EPS is -0.24, and the Price-to-Earnings (P/E) ratio is null, indicating the company is not currently profitable on a per-share basis.
No Revenue and Negative Net Income
The company reported zero revenue for TTM, 2024, and 2023, coupled with significant net losses, suggesting a lack of commercialization or operational revenue generation.
Calendar
Profile
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.
Seasonals
Price Target
16.00 USD
The 39 analysts offering 1 year price forecasts for ESLA have a max estimate of 16.00 and a min estimate of 16.00.
Financial Position Analysis
Ownership
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Long-standing primary battery cell supplier for Tesla's electric vehicles and energy storage solutions, a critical partner.
Weight: 98
Leading global electric vehicle (EV) and battery manufacturer, a direct and significant competitor to Tesla across multiple markets and battery tech.
Weight: 95
Major legacy automaker with an aggressive and significant global electric vehicle transition strategy, positioning it as a key competitor to Tesla.
Weight: 93
Significant investment in electric vehicles (EVs) and autonomous driving (Cruise LLC), making it a direct competitor to Tesla in key areas.